Skip to main content

Advertisement

ADVERTISEMENT

news

a caregiver speaks with a doctor
News
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Patient survey
News
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
depression stock photo
News
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Conference presenter
News
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
a doctor and patient sit on couches talking
News
01/05/2024
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable...
01/05/2024
Psych Congress Network
Adding Drug-Drug Interactions, Lifestyle Factors Boosts Pharmacogenomics Guidance
News
12/04/2023
Incorporating drug-drug interactions and lifestyle factors into pharmacogenomics-guided medication management contributed to improved remission rates in patients with major depressive disorder, according to a poster presentation at Psych...
Incorporating drug-drug interactions and lifestyle factors into pharmacogenomics-guided medication management contributed to improved remission rates in patients with major depressive disorder, according to a poster presentation at Psych...
Incorporating drug-drug...
12/04/2023
Psych Congress Network
stock depression
Conference Poster Highlight
10/31/2023
Hypersomnolence, insomnia, and sleep dissatisfaction predicted the recurrence of MDD over 3 years, according to a poster presentation at Psych Congress.
Hypersomnolence, insomnia, and sleep dissatisfaction predicted the recurrence of MDD over 3 years, according to a poster presentation at Psych Congress.
Hypersomnolence, insomnia, and...
10/31/2023
Psych Congress Network
schizophrenia treatment
News
10/25/2023
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting...
10/25/2023
Psych Congress Network
schizophrenia treatment
News
10/25/2023
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting...
10/25/2023
Psych Congress Network
depression stock photo
Psych Congress Poster Brief
10/10/2023
Patients with MDD who responded to treatment with zuranolone said they experienced rapid improvement in depressive symptoms and in their daily lives, Psych Congress poster states.
Patients with MDD who responded to treatment with zuranolone said they experienced rapid improvement in depressive symptoms and in their daily lives, Psych Congress poster states.
Patients with MDD who responded...
10/10/2023
Psych Congress Network

Advertisement